Souhil Lebdai1, Victor Basset2, Julien Branchereau3, Alexandre de La Taille4, Vincent Flamand5, Thierry Lebret6, Thibaut Murez7, Yann Neuzillet6, Guillaume Ploussard8, François Audenet9. 1. Department of Urology, University Hospital of Angers, 4, rue Larrey, 49933, Angers, France. souhil.lebdai@gmail.com. 2. Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Hopital Saint Lois, Paris, France. 3. Department of Urology, CHU Nantes Hôtel Dieu, Nantes, France. 4. Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Université Paris XII Val de Marne, Créteil, France. 5. Department of Urology, Lille University Hospital, Lille Nord de France University, Lille, France. 6. Department of Urology, Foch Hospital, Université Versailles St Quentin en Yvelines, Suresnes, France. 7. Department of Urology, Hôpital Lapeyronie, Montpellier, France. 8. Department of Urology, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France. 9. Department of Urology, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.
Abstract
PURPOSE: To present a systematic review of the different therapeutic sequences in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Evidence acquisition on therapeutic sequences in mCRPC was performed by a MEDLINE search using combination of the following key words: "prostate cancer," "metastatic," "castration resistant," "enzalutamide," "abiraterone," "treatment sequencing," "cabazitaxel," "docetaxel." A total of 17 studies were included for analysis. RESULTS: Different sequences have been reported for the treatment of mCRPC: docetaxel after abiraterone, cabazitaxel after docetaxel and abiraterone, abiraterone after cabazitaxel and docetaxel, abiraterone after docetaxel and enzalutamide, and enzalutamide after docetaxel and abiraterone. There are arguments from the preclinical observations suggesting a cross-resistance between docetaxel and abiraterone, and between abiraterone and enzalutamide in mCRPC. Despite limitations, several retrospective clinical reports support these data. CONCLUSION: No study of high level of evidence is available to support any recommendation on sequential treatment for mCRPC. There are only clues that prospective clinical studies need to confirm.
PURPOSE: To present a systematic review of the different therapeutic sequences in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Evidence acquisition on therapeutic sequences in mCRPC was performed by a MEDLINE search using combination of the following key words: "prostate cancer," "metastatic," "castration resistant," "enzalutamide," "abiraterone," "treatment sequencing," "cabazitaxel," "docetaxel." A total of 17 studies were included for analysis. RESULTS: Different sequences have been reported for the treatment of mCRPC: docetaxel after abiraterone, cabazitaxel after docetaxel and abiraterone, abiraterone after cabazitaxel and docetaxel, abiraterone after docetaxel and enzalutamide, and enzalutamide after docetaxel and abiraterone. There are arguments from the preclinical observations suggesting a cross-resistance between docetaxel and abiraterone, and between abiraterone and enzalutamide in mCRPC. Despite limitations, several retrospective clinical reports support these data. CONCLUSION: No study of high level of evidence is available to support any recommendation on sequential treatment for mCRPC. There are only clues that prospective clinical studies need to confirm.
Authors: Avishay Sella; Tal Sella; Avivit Peer; Raanan Berger; Stephen Jay Frank; Eli Gez; David Sharide; Henry Hayat; Ekaterina Hanovich; Svetlana Kovel; Eli Rosenbaum; Victoria Neiman; Daniel Keizman Journal: Clin Genitourin Cancer Date: 2014-06-10 Impact factor: 2.872
Authors: Arthur C Houts; Daniel Hennessy; Mark S Walker; Leonardo Nicacio; Stephen F Thompson; Paul Je Miller; Bradley G Somer Journal: J Community Support Oncol Date: 2014-09
Authors: Sebastian Christoph Schmid; Alexander Geith; Alena Böker; Robert Tauber; Anna Katharina Seitz; Markus Kuczyk; Christoph von Klot; Jürgen Erich Gschwend; Axel Stuart Merseburger; Margitta Retz Journal: Adv Ther Date: 2014-01-18 Impact factor: 3.845
Authors: Rahul Aggarwal; Anna Harris; Carl Formaker; Eric J Small; Arturo Molina; Thomas W Griffin; Charles J Ryan Journal: Clin Genitourin Cancer Date: 2014-03-28 Impact factor: 2.872
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Klaus Brasso; Frederik B Thomsen; Andres J Schrader; Sebastian C Schmid; David Lorente; Margitta Retz; Axel S Merseburger; Christoph A von Klot; Martin Boegemann; Johann de Bono Journal: Eur Urol Date: 2014-08-06 Impact factor: 20.096
Authors: Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm Journal: Cancer Res Date: 2012-11-01 Impact factor: 12.701
Authors: Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard Journal: Cancer Res Date: 2012-03-12 Impact factor: 12.701
Authors: Javier Puente; Urbano Anido; Miguel Ángel Climent; Enrique Gonzalez-Billalabeitia; Nuria Lainez; Julio Lambea; José Pablo Maroto; Maria Jose Mendez-Vidal; Álvaro Montesa; Angel Rodriguez; Curro Zambrana; Aránzazu González-Del-Alba Journal: Ther Adv Med Oncol Date: 2020-05-27 Impact factor: 8.168